James E. Barrett, Ph.D.
Professor and Chair
Director, Program in Drug Discovery and Development
Ph.D. (1971) Pennsylvania State University
Phone: 215-762-2398
Email: jbarrett@drexelmed.edu
A major new initiative in the department is to launch a new program in Drug Discovery and Development. This program will provide an opportunity for students at Drexel University to have an in-depth exposure to the many different facets of drug discovery and development ranging from the early identification of a molecular target, through the multiple steps involved in preclinical assessment and development, and ultimately to approval and post-marketing activities. The objective is to provide opportunities for students in both M.S. and Ph.D. programs who may be interested in a career in the pharmaceutical and/or biotechnology industry to acquire formal exposure to these processes in the context of their graduate training.
In addition to this development of this program, other research interests involve behavioral pharmacology, animal models of neuropsychiatric and neurological disorders, cognitive neuroscience, CNS plasticity and pain.
Recent publications:
Schechter, L.E., Smith, D.L., Rosenzweig-Lipson, S., Sukoff, S., Dawson, L.A., Marquis, K., Jones, D., Piesla, M., Andree, T., Nawoschik, S., Harder, J.A., Womack, M.D., Buccafusco, J., Terry, A.V., Hoebel, B., Rada, P., Kelly, M., Abou-Gharbia, M., Barrett, J.E., Childers, W. Lecozatan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes precognitive effects. Journal of Pharmacology and Experimental Therapeutics 2005, 314, 1274-1289.
Rosenzweig-Lipson, S., Zhang, J., Mazandarani, H., Harrison, B., Sabb, A., Sabalski, J., Stack, G., Welmaker, G., Barrett, J.E., and Dunlop, J. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Research 2006, 1073-1074, 240-251
Barrett, J.E. Behavioral determinants of drug action: The contributions of Peter B. Dews. Journal of the Experimental Analysis of Behavior 2006, 86, 359-370.
Rowe, W., Blalock, E., Chen, K., Kadish, I., Wang, D., Barrett, J., Porter, N., Rose, G. and Landfield, P. Hippocampal Expression Analyses Reveal Selective Association of Immediate-Early, Neuroenergetic, and Myelinogenic Pathways with Cognitive Impairment in Aged Rats. Journal of Neuroscience 2007, 27, 3098-3110.
Marquis,K.L., Sabb, A.L., Logue, S.F., Brennan, J.A., Piesla, M.J., Comery, T.A., Grauer, S.M., Ashby, C.R., Jr., Nguyen, H.Q.; Dawson, L.A., Barrett, J.E., Stack, G., Meltzer, H.Y., Harrison, B.L., and Rosenzweig-Lipson, S. WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): A Novel 5-HT2C Receptor Selective Agonist with Preclinical Antipsychotic-like Activity. Journal of Pharmacology and Experimental Therapeutics 2007, 320, 486-496.
|